The objective of this study was to examine the effects of dihydropyridine calcium antagonist therapy on 24-h baroreflex sensitivity. Twenty-three patients with moderate essential hypertension were studied before and during acute (10 patients) and chronic (21 patients) treatment with a dihydropyridine calcium antagonist (nifedipine, nicardipine or felodipine) as monotherapy in a dose titrated to produce a fall in mean cuff pressure of at least 10%. Twenty-four hour unrestricted ambulatory intra-arterial blood pressure (IABP) and heart rate (R-R interval) were monitored. Baroreflex sensitivity (BRS) was assessed throughout the 24-h period by off-line computer analysis of spontaneous variations in IABP and R-R interval. During acute first dose treatment with a calcium antagonist there was a significant fall in blood
Introduction
We have re-analysed previously published data from our department [1] [2] [3] on patients given calcium antagonists both acutely and chronically, to determine the influence of dihydropyridine therapy on continuous, spontaneous 24-h baroreflex sensitivity (BRS). Despite having been used routinely in the treatment of hypertension and ischaemic heart disease for 20 years, the safety of calcium antagonists has recently been called into question. 4 It has been suggested that the long-term use of calcium antagonists is associated with an increase in mortality and myocardial infarction. Amongst the pathophysiological mechanisms proposed whereby calcium antagonists increase these risks is an increase in sympathetic activity. 4 Initial dosing with dihydropyridine calcium antagonists is associated with a reflex tachycardia, 5 attributable to a baroreflex mediated increase in sympathetic activity and reduction in vagal activity in response to the lower level of blood pressure. However, these changes are attenuated by the effects of baroreceptor resetting, whereby there is a shift in the function curve relating afferent baroreceptor activity to blood pressure, in the direction of the prevailing arterial pressure; estimates of the time course of baroreceptor resetting vary from minutes 6 to days or weeks. 7 Thus, as a result of resetting, the deleterious autonomic effects associated with initial doses of dihydropyridines may not persist with chronic therapy. In addition to the effects of resetting, the autonomic effects of dihydropyridine therapy may be reflected by changes in the gain or sensitivity of the baroreceptor reflex. Baroreflex sensitivity, measured using the early (Ͻ10 sec) heart rate responses to fluctuations in blood pressure, is predominantly a measure of cardiac vagal activity although persisting sympathetic activation would be expected to exert an inhibitory influence. 8 BRS is impaired in hypertension, but the influence of chronic dihydropyridine therapy on BRS is unclear and the results of previous studies on the effects of calcium antagonists have been inconsistent. [1] [2] [3] 9 Patients and methods Twenty-three patients were included in this reanalysis. Ten were studied after an acute dose of a dihydropyridine calcium antagonist and 21 after chronic therapy. All 23 patients had been recruited from our hypertension clinic, their mean age was 47 years and there were eight women. In order to be included in the original studies, the patients needed a casual blood pressure of greater than 140/90 mm Hg on at least three separate occasions over a period of 1 month or more. No patient had evidence of target organ damage defined as clinical evidence of ischaemic heart disease or cerebral vascular disease, left ventricular hypertrophy, renal impairment or accelerated hypertension. An underlying cause for hypertension was excluded in each case. The patients were either untreated or had not received antihypertensive therapy for a minimum of 2 weeks before entering the study.
The patients were studied in a hospital ward under standardised conditions; 10 they were freely ambulant throughout and they recorded their sleeping time in a diary. Observations were made under control conditions and following the acute and chronic administration of calcium channel blockers. On each visit, intra-arterial blood pressure (IABP) and ECG were measured continuously throughout a 24-h period. Blood pressure was measured directly and continuously from the brachial artery on a portable analogue tape recorder as previously described by us. 11 No complications of the intra-arterial technique were encountered in these patients. All patients gave informed consent to these investigations, which were approved by the hospital Ethics Committee.
Calcium antagonists
Nicardipine: The IABP recordings of 10 patients (mean age 48 years, six males, four females) were analysed. These comprised eight patients as previously published 1 and a further two patients from whom data were available only for the acute arm of the study and who were not included in the previous publication. In each patient, a 24-h IABP recording was taken in the untreated control state and continued for a further 8 h after receiving 30 mg of nicardipine orally. Patients were then treated for a period of 8 weeks with nicardipine at a dose of 20-40 mg t.d.s. The dose was titrated in the hypertension clinic to produce a fall in mean cuff pressure of at least 10%. A further 24-h IABP recording was taken on completion of the 8-week chronic treatment period.
Nifedipine: The IABP recordings of eight patients (mean age 42 years, seven males, one female) were analysed (the original publication 3 comprised nine complete data sets of which one was no longer available). The patients had received nifedipine capsules for 16 weeks in a titrated dose of 10-20 mg t.d.s. Twenty-four hour IABP recordings were taken in the untreated control state and on completion of the 16-week chronic treatment period.
Felodipine: The IABP recordings of five patients (mean age 52 years, two males, three females) were analysed (the original publication 2 comprised six complete data sets of which one was no longer available). The patients were treated for 6 weeks with a titrated dose of 5-7.5 mg t.d.s. Twenty-four hour IABP recordings were taken in the untreated control state and on completion of the 6-week chronic treatment period.
Determination of baroreflex sensitivity
Spontaneous BRS was assessed by analysis of the 24-h IABP recordings by an adaptation of the method originally described by Parati et al, 12 as we have previously reported. 13 Each IABP recording was sampled at 125 Hz, digitised into 12 bits and analysed by an Apple Macintosh micro-computer running Lab View software. A specifically designed programme identified sequences of three or more consecutive beats with spontaneous progressive increases in systolic IABP accompanied by progressive increases in pulse interval ('positive sequences'). Equally the programme identified sequences of three or more consecutive beats with spontaneous decreases in systolic IABP accompanied by progressive decreases in pulse interval ('negative sequences'). The threshold for change was set at 1 mm Hg for IABP and 8 msec for pulse interval. The numbers of positive and negative sequences were calculated for day, for night and for the 24-h period. The slope of the relationship between the IABP and pulse interval during each sequence was taken to be a measure of spontaneous BRS; the minimum r value that was accepted was 0.8. The means of these values for day, for night and for the entire 24-h period were calculated.
Statistical methods
Data of BRS were subjected to logarithmic transformation to correct for skewing of the distribution. Comparisons between waking and sleeping states were made by unpaired Student's t-test. Comparisons between control and chronically treated states were made by paired Student's t-test. In the acute study, comparisons between control, acutely treated and chronically treated states were made using ANOVA. A P value of less than 0.05 was considered to be significant.
Results

Blood pressure and heart rate
Acute study: Nicardipine given acutely produced a significant reduction in blood pressure and a significant increase in heart rate ( Table 1) . Values are mean ± s.d. MBP, mean intra-arterial blood pressure. *P Ͻ 0.001 compared to awake blood pressure; †P Ͻ 0.001 compared to awake heart rate.
Chronic study: Twenty-one pairs of IABP recordings (before and after chronic therapy) were available: two recordings in the nicardipine group were incomplete and unsuitable for analysis. All calcium antagonists significantly reduced blood pressure without a significant increase in heart rate during the waking and sleeping hours ( Table 2) .
Frequency of sequences
There was a consistent trend towards a greater number of negative sequences than positive sequences. The frequency of sequences and the ratio of positive to negative sequences did not change after treatment (either chronic or acute). The frequencies of positive and negative sequences before and after chronic treatment are shown in Table 3 .
Baroreflex sensitivity
Acute study: BRS was calculated continuously for 4 h after an acute oral dose of nicardipine and showed a significant reduction from control values ( Figure 1 ).
Chronic studies:
There was an increase in BRS after chronic therapy; this was a consistent trend for each of the individual drugs, and was statistically significant for the group as a whole. Table 4 shows the group mean data during awake and sleeping hours, with values of BRS derived separately from positive sequences (baroreflex loading) and negative sequences (baroreflex unloading). BRS derived from negative sequences was significantly greater than BRS derived from positive sequences, both before and after treatment. Figure 2 demonstrates the BRS behaviour over 24 h, before and after chronic dihydropyridine calcium antagonist therapy. 
Discussion
We have re-analysed our previously published data 1-3 concerning the effects of three dihydropyridine calcium antagonists on 24-h IABP and heart rate in unrestricted patients. The main aim of this reanalysis was to produce estimations of continuous BRS for 24-h periods which included sequences in which both blood pressure and pulse interval increased (baroreceptor loading) or decreased (baroreceptor unloading). In our original reports of these studies, we demonstrated that calcium channel blocking drugs given as monotherapy significantly reduced 24-h blood pressure levels without an increase in heart rate. We also examined the sinoaortic baroreceptor heart rate reflex, using phenylephrine according to the 'Oxford method' 14 and found that while resetting occurred within 1 week of starting treatment there was no consistent change in reflex sensitivity. Several conclusions can be drawn from our latest results. Firstly, nicardipine given acutely produces a significant fall in blood pressure; this is associated with a significant increase in heart rate and a significant decrease in BRS, which is interpret as indicating a reflexogenic increase in sympathetic activity and decrease in vagal activity to the sinus node. Secondly, following chronic treatment with nicardipine, felodipine or nifedipine, blood pressure remained low whilst the heart rate was reduced and the BRS was increased compared to control levels. These effects were evi- Values are mean ± s.d. *P Ͻ 0.001 compared to awake BRS; †P Ͻ 0.001 compared to positive sequences.
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Figure 2
The 24-h pattern of spontaneous BRS in 21 patients before (untreated) and 6-16 weeks after (chronic) oral dihydropyridine calcium antagonist therapy (nicardipine n = 8, nifedipine n = 8, felodipine n = 5). Mean spontaneous BRS is plotted for each hour of day and night. The nocturnal rise in BRS is evident both before and after treatment. Values are mean ± standard error of mean. dent at 6 weeks and still present after 16 weeks of treatment. These chronic findings indicate re-setting in addition to increased sensitivity of the sino-aortic baroreceptor heart rate reflex. Thirdly, the diurnal pattern of BRS was preserved during treatment with calcium antagonists. Before treatment, the BRS during sleep was significantly higher than during daytime and the increase in BRS after chronic therapy was greater during sleep than during the waking period. During waking hours, exercise and the alerting reaction may inhibit BRS 15 so that the extent of its modulation by drugs may be masked. In contrast, during sleep there are less inhibitory influences on BRS, allowing the enhancing effects of calcium channel blockers to become most apparent.
In our previous studies, we measured BRS with bolus injections of phenylephrine using the 'Oxford method'; 14 there was an increase in BRS after chronic therapy with nifedipine, but no significant differences in BRS after nicardipine or felodipine. However in this re-analysis we found consistent increases in spontaneous BRS with each of the three drugs. We believe that this apparent discrepancy is explained by the large number of ramps used for the measurement of spontaneous BRS in contrast to the small number of ramps used with the 'Oxford method'. The larger number of ramps used by sequence analysis and the fact that BRS is estimated throughout a 24-h period may have provided increased power to detect an increase in BRS, which was not consistently evident in our earlier studies.
In addition there may be other differences between sequence analysis and the 'Oxford method'. The magnitudes of the changes in blood pressure with sequence analysis are typically of the order of a few mm Hg whilst the vasoactive drug methods usually induce larger changes of 10 to 20 mm Hg. Experience with the 'Oxford method' shows that during a pressure rise after vasoactive drug injection, the pulse interval may not lengthen for two or three beats with an apparent threshold of pressure below which pressure variations are tolerated without immediate reflex activation.
14 The first few beats of a pressure pulse relationship are often therefore flatter than the first pressure rise clearly falling above 'control' variation. Thus the two methods may have assessed gain at different sites on the baroreflex curve and obtained different values. Finally, our early studies with the 'Oxford method' examined only baroreflex loading after rises in blood pressure generated by phenylephrine injection whilst in the current re-analysis with the sequence method we examined both rises and falls in blood pressure. When the effects of baroreflex loading and unloading were analysed separately, BRS values were higher if derived from negative sequences, and these tended to occur more frequently than positive sequences. Previous authors have found differences in the gain of baroreflex tachycardia and bradycardia, with varying results depending upon the species studied, the method used to determine BRS and the resting heart rate. 16, 17 Consistent with our findings, studies in rats, rabbits and humans found that BRS measured by the vasoactive drug method was much greater during unloading compared to loading of the baroreceptors; 16,17 the reverse trend was found when BRS was normalised to take account of heart rate, indicating that the higher BRS for unloading is largely due to a greater heart rate change in the tachycardia compared with the bradycardia direction. 17 Previous studies using sequence analysis have found that BRS values derived from baroreflex loading were comparable to those derived from unloading. 12 Importantly, in our study the proportion of positive and negative sequences did not change after treatment and thus the differences between positive and negative sequences do not account for the finding that BRS was increased after dihydropyridine therapy.
Is the chronic effect of calcium antagonists on heart rate and BRS due to a decrease in sympathetic activity or an increase in vagal tone? The literature is conflicting on the question of persisting sympathetic 193 hyperactivity following calcium antagonism, but the majority of reports suggest that hyperactivity does persist even with the long acting preparations. 5, 9, [18] [19] [20] [21] Recently, it has been shown that peripheral muscle sympathetic activity as recorded by microneurography was increased over baseline after 4 weeks treatment with amlodipine. 21 It has been suggested that one reason for the persisting sympathetic activity with short acting calcium antagonists relates to the profile of induced blood pressure reduction with formulations which cause rapid falls in blood pressure and doses or dosing intervals which result in substantial peak:trough ratios, thus causing increases in sympathetic activity in the initial hours after dosage. Conversely, long acting calcium antagonists without such dose related fluctuations in blood pressure do not cause increases in plasma noradrenalin. However, as already mentioned other indices of sympathetic activity are increased, even with the long acting preparations.
What is consistent amongst the literature is the fact that there is a dissociation between heart rate changes and other measures of sympathetic activity such as plasma catecholamines. The long-term adaptation of heart rate occurs despite a persistent increase in sympathetic nervous tone. This may be explained by a direct effect of the calcium channel blockers on the sinus node. Although this effect has not been demonstrated in intact man, there is considerable supportive evidence from animal studies. Both nifedipine and nicardipine have been shown to reduce isolated pacemaker activity in rabbit sinoatrial tissue. [22] [23] [24] These effects may contribute to the reduction in heart rate seen with chronic therapy and may also modulate the sensitivity of the baroreceptor heart rate reflex. An alternative explanation for the changes in heart rate and BRS after chronic therapy is an increase in vagal activity; the central nervous system is a potential site where calcium antagonists may influence cardiovascular autonomic control. Calcium antagonists accumulate in the brain after intravenous injection; 25 channels sensitive to these drugs are present in the brain [26] [27] [28] and calcium ions are involved in the release of neurotransmitters in the central nervous system. Higuchi et al 29 demonstrated that organic calcium antagonists alter autonomic function by acting on the brain stem neurones in rats. Their studies demonstrated that intra-cisternal administration of diltiazem and verapamil produced dose-related decreases in arterial pressure and heart rate. These responses to calcium antagonists were absent or markedly attenuated in rats previously treated with six hydroxidopamine or with bilateral electrolytic lesions of the nucleus tractus solitarius (NTS), but were preserved in rats treated with atropine or with sham NTS lesions. These results suggested that organic calcium antagonists produced excitation of neurones within the NTS resulting in withdrawal of sympathetic activity and a decrease in blood pressure and heart rate. Whether the effects of calcium antagonists on brain stem neurones are involved in their therapeutic action is speculative and would not necessarily result in a differential effect on the cardiac and systemic sympathetic activity.
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A further explanation for the changes in heart rate and BRS after chronic therapy could be a direct effect of calcium antagonists on the carotid sinus baroreceptors. Heesch and colleagues studied the effects of calcium antagonists on isolated carotid sinus baroreceptors and the baroreflex by applying the drugs locally to the carotid sinus region. 30 They demonstrated that verapamil and nifedipine had direct effects on the carotid sinus baroreceptors manifested in the reflex control of the efferent renal sympathetic nerve activity, whereas reflex control of blood pressure and heart rate was not affected. There was a difference between the two drugs; verapamil decreased and nifedipine increased the sensitivity of the carotid sinus baroreceptors and the baroreflex. However, it should be remembered that these experiments were designed to exclude the central nervous system and systemic effects of these drugs.
Study limitations
This was a retrospective re-analysis of data obtained from our own published studies of the effects of short acting dihydropyridine calcium channel antagonists, and one serious limitation is that there was no placebo phase in the studies. This is important because in addition to the effects of treatment, the second recording may have been influenced by a placebo response or by familiarisation or order effects which are known to influence indirect blood pressure measurements. However in a previous publication 31 24-h IABP and heart rate (from which BRS is derived in our study) were not influenced by any of these effects and the authors concluded that placebo control was not required for trials in which the 24-h IABP technique was used. Given those findings we believe that the lack of placebo in our study is unlikely to account for our findings.
Conclusions
Reduced vagal tone as reflected by reduced BRS is an adverse prognostic indicator following myocardial infarction and in heart failure. 32, 33 Previous authors have suggested that reduced BRS may underlie the recent reports that chronic therapy with calcium antagonists is associated with an adverse prognosis. 4 Our studies indicate that following the chronic use of calcium antagonists there is no reflex tachycardia and baroreflex sensitivity is increased. We would interpret this as a beneficial feature of these drugs. Conversely, acute administration of calcium antagonist is associated with a reflex tachycardia and reduced BRS, which may increase the risk of dangerous arrhythmias in vulnerable patients.
